‘The Top Line’ podcast: Biogen’s overhaul reaches CEO level; the most influential people in biopharma; plus this week’s headlinesnews2022-05-04T14:10:20+00:00May 4th, 2022|Fierce Pharma|
Next Biogen CEO’s most-prized expertise? Dealmaking experience, investors saynews2022-05-04T13:30:18+00:00May 4th, 2022|Fierce Pharma|
Dupixent makers Sanofi, Regeneron want you to ‘Du More’ in latest asthma DTC campaignnews2022-05-04T10:03:21+00:00May 4th, 2022|Fierce Pharma|
Teva cuts sales guidance amid competitive pressures, currency exchange woesnews2022-05-03T20:03:18+00:00May 3rd, 2022|Fierce Pharma|
Bayer’s Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new usenews2022-05-03T19:40:13+00:00May 3rd, 2022|Fierce Pharma|
Pfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demandnews2022-05-03T15:35:37+00:00May 3rd, 2022|Fierce Pharma|
Incyte says it has added 2nd manufacturing site to remedy Opzelura production problemsnews2022-05-03T14:56:22+00:00May 3rd, 2022|Fierce Pharma|
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch programnews2022-05-03T14:45:57+00:00May 3rd, 2022|Fierce Pharma|
Bexson expands on-body ketamine delivery work into mental healthnews2022-05-03T14:39:01+00:00May 3rd, 2022|Fierce Pharma|
Biogen sends CEO to the exit, abandons Aduhelm sales team in $1B overhaulnews2022-05-03T13:46:43+00:00May 3rd, 2022|Fierce Pharma|
